Sanofi : A largely predictable slowdown in Q2
>Destocking in Q2, guidance not at risk - Sanofi is due to report its Q2 2020 results on 29 July which will be characterised, like those of its peers, by a slowdown in its business. This is due to a Q1 performance boosted by marked stockpiling effects/pre-orders in anticipation of the lockdown imposed by western states. Stockpiling in distribution channels linked to the COVID-19 pandemic represented around half of Q1 2020 sales growth (i.e. around 3.3% at constant cur...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.